$14.49▴ 0.00%
End-of-day close · 2026-04-24
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$33.15MTTM operating cash
Pre-profit
It generates operating cash even though it has no reported profit yet.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+30.9%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Moderatedebt to assets
Watch
Elevated leverage worth keeping an eye on.
More coming: dilution / share-count creep.
✦ The read
Amicus Therapeutics, Inc. is pre-profit. It generates operating cash even though it has no reported profit yet. Revenue is growing strongly year over year. Elevated leverage worth keeping an eye on.
Key numbers
Valuation
EPS (TTM)$-0.09
TTM (trailing 12 months, through fiscal Q4 FY2025)
Profitability
Net margin-4.3%
TTM (trailing 12 months, through fiscal Q4 FY2025)
Size
Revenue (TTM)$634.21M
TTM (trailing 12 months, through fiscal Q4 FY2025)
Signals and key numbers are from the fiscal Q4 FY2025 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.